Investor Year End Bulletin (2018)

Investor Year End Bulletin (2018)

Dear investor,

Before you unwind for the Holidays, we would like to take this opportunity to thank you for your support in 2018. Because of your continued support, 2018 has been an outstanding year of growth for the Fund Singapore. We wish you a happy Holiday Season and a great New Year’s celebration.

To conclude this business year, we would like to give you an End-of-Year Rundown of our activities, events and business developments.

Crowdfunding has become a thriving and durable growth industry in Asia. Globally, funds raised via crowdfunding have total over US$9.4B in the first half of 2018 over approximately 8.8M campaigns.

Did you know that crowdfunding in Asia – albeit still in its infancy – is poised to catch up quickly at a continued growth rate averaging 30% year-on-year from 2018-2022? Transaction value in APAC alone hit a stunning US$7.6B between 2017 and 2018 – about 85% of global deals.

2018 OUTCOMES AND SUCCESSES

Unveiling of a larger management office
In June 2018, Fund Singapore bided goodbye to our first office space at OCBC Centre and traded it for a new, bigger home at Bank of Singapore Centre. The office was unveiled to our shareholders, partners and clients on 7th June 2018 in conjunction with our 2nd anniversary.

Campaign Success Story
Medical technology firm Biolidics Limited, a cancer diagnostic solutions developer formerly known as Clearbridge BioMedics is an investee company onboard the Fund Singapore platform sometime in Q2 this year for funding. The company has recently lodged a preliminary prospectus on 23rd November 2018 for a planned initial public offering (IPO) on the Singapore Exchange’s Catalist Board. More details such as the amount to be raised, and timing of the offering will be announced at a later date.

The IPO proceeds will be used to develop the clinical applications and clinical services customer segment for Biolidics’ products, as it has sold them mainly to academic and research institutions so far.

Fund Singapore will be working closely with Biolidics Limited to explore other collaborative opportunities in the future such as the offering of their services to our investors.

From Singapore to the region
This year, we have expanded into Australia and Japan. In the coming months, we will work hard to bring you access to an increased number of exciting investment opportunities from our offices across the region. Very soon, investors of Fund Singapore will be able to explore investment projects from specialised industries of the respective countries e.g., robotics projects in Japan and agricultural ones in Australia.

Awards and Accomplishments
Fund Singapore participated in this year’s INVEST Fair as a Platinum Sponsor. Crowdfunding is still largely a novel financial concept to Singapore hence, our company’s goal was to curate a series of activities to introduce and familiarise attendees to it. During the 2-day long exhibition, we invited all our investee companies funded in 2018 to showcase the important work they do alongside us.

Moreover, Fund Singapore won the top award for ‘Most Preferred Crowdfunding Platform’ in Singapore by The Business Times and ShareInvestor Awards. Once again, a big thank you to our existing and new investors who got involved either by casting votes or visiting our exhibition booth.

What’s makes Fund Singapore Unique?
Fund Singapore does not view itself merely as a crowdfunding platform that marries businesses and investors. It holds a bigger vision to create an ecosystem across the Asia Pacific. As it invests in local businesses, it aims to form synergies between the investee companies to obtain better efficiencies, leveraging on each country’s strengths and support to ensure that they have good success and growth.

Office Closure
Kindly note Fund Singapore’s Management office will be closed from Thursday, 20th December through 1nd January 2019, Wednesday for the festive season. During this period, please expect delayed replies to any emails you may send to our team. For urgent matters, please contact the relevant person via their direct email address.

Leave a Comment